Pfizer Collaboration Agreement

As part of the agreement, CENTOGENE and Pfizer will work together to recover the data repository and agree together on all collaborative research projects to support the results of data extraction. Centogene receives a down payment and may receive additional payments for future cooperative research projects. Individual deposit data is managed, protected and shared with Pfizer in accordance with international data protection rules. „Today`s agreement with Pfizer is one of many steps we are taking to rapidly develop a sustainable presence in infectious disease research and development, combining our deep understanding of the immune system to treat diseases with the most advanced technologies and the important infrastructure we have put in place over many years to develop immunotherapy treatments.“ said Professor Ugur Sahin, co-founder and CEO of BioNTech. „A significant presence in infectious diseases contributes to the creation of a global immunotherapy society that offers more effective and accurate immunosup primary immunosup primary approaches for the prevention and treatment of serious diseases such as influenza prevention and cancer treatment.“ NEW YORK – MAINZ, Germany— (BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. administration`s goal of Operation Warp Speed to begin delivering 300 million doses of COVID-19 vaccines in 2021. As part of the agreement, the U.S. government receives 100 million doses of BNT162, the candidate for the coVID-19 vaccine jointly developed by Pfizer and BioNTech, after Pfizer has successfully obtained the approval or approval or emergency approval of the U.S.

Food and Drug Administration (FDA). This press release contains forward-looking information on ARM-based influenza vaccines and the cooperation between Pfizer and BioNTech in the development of these vaccines, including their potential benefits, which present significant risks and uncertainties that could cause actual results to differ materially from expressed or implied results.

Kommentieren ist momentan nicht möglich.